By Lina carolina 
A groundbreaking collaboration between Canadian researchers has unveiled a revolutionary method for swiftly identifying personalized treatment strategies for young cancer patients. This innovative approach involves cultivating a patient’s tumour within chicken eggs and then meticulously analyzing its protein composition. This pioneering technique, the first of its kind in Canada to integrate these two methodologies for timely drug identification and testing, promises to accelerate the delivery of potentially life-saving therapies for children facing aggressive and treatment-resistant cancers.
The research, published today in the esteemed journal EMBO Molecular Medicine, highlights the profound impact of proteomics, the study of proteins, as a vital complement to genomics, the study of genes, in the realm of real-time cancer treatment. This collaborative endeavor is a cornerstone of the PROFYLE (PRecision Oncology For Young peopLE) initiative, a crucial component of the Canadian pediatric cancer network ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship). ACCESS itself is a vast undertaking, uniting over 30 research and funding organizations and more than 100 investigators from across Canada with the singular mission of enhancing cancer outcomes for children and young adults.
The Challenge of Rare Pediatric Cancers
The study focused on an unnamed young patient diagnosed with a rare pediatric cancer that had proven intractable to conventional treatment regimens. Standard chemotherapy had been administered without success, and subsequent genomic testing revealed the tumour had developed resistance to a previously identified drug, leaving clinicians with few viable options. It was in this critical juncture that the research team, led by co-lead authors Dr. Georgina Barnabas, a postdoctoral researcher in Dr. Philipp Lange’s laboratory, and Tariq Bhat, a PhD student in Dr. James Lim’s laboratory, turned to proteomics.
"With genomics alone, we couldn’t find a clear treatment option," explained Dr. Philipp Lange, a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BC Children’s Hospital Research Institute (BCCHR). "However, by examining the tumour’s proteins, we identified a critical metabolic vulnerability that we could target with an already approved drug."
Proteomics: Unveiling the Functional Engine of Tumours
While genes provide the blueprint for cellular function, it is proteins that are the actual workhorses, carrying out the vast majority of cellular processes. Most pharmaceutical interventions are designed to modulate the activity of these proteins. The research team hypothesized that by delving into the proteomic landscape of the tumour, they might uncover hidden dependencies and vulnerabilities that genetic analysis alone might overlook. This proved to be a prescient insight.
Their proteomic analysis revealed that the patient’s tumour was heavily reliant on a specific enzyme, identified as SHMT2, for its metabolic functions. This discovery was pivotal, as it presented a clear therapeutic target. The researchers proposed a novel strategy: utilizing sertraline, a commonly prescribed antidepressant known for its ability to inhibit SHMT2, thereby disrupting the tumour’s primary energy supply.
The Chicken Egg Avatar: A Miniature Tumour Sandbox
To rigorously test this hypothesis and assess the efficacy of sertraline in a controlled environment, the team employed a sophisticated technique: growing a small sample of the patient’s tumour on a chicken egg. This method, part of the BRAvE (Better Responses through Avatars and Evidence) initiative at BCCHR, effectively creates a "tumour avatar" – a living, growing representation of the patient’s cancer outside the body.
"This technique significantly accelerates the process of evaluating a treatment option, something that would be virtually impossible with traditional methods," stated Dr. James Lim, another senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR. "We were able to rapidly confirm whether the drug identified through proteomics could indeed be effective against the patient’s specific tumour."
The creation of these tumour avatars on chicken eggs provides a crucial bridge between laboratory research and clinical application. It allows for the rapid screening of multiple drug candidates and combinations, offering a personalized drug response profile within weeks, a timeline that is often a critical factor in pediatric oncology where disease progression can be swift.
A Collaborative Endeavor: PROFYLE and ACCESS
The success of this study is a testament to the power of interdisciplinary collaboration and the strategic initiatives in place within Canadian pediatric cancer research. The PROFYLE initiative, under the umbrella of ACCESS, is designed to foster such groundbreaking work. It brings together a diverse array of expertise, from molecular biologists and oncologists to bioinformaticians and clinical trial specialists, all united by a common goal: to translate scientific discoveries into tangible benefits for young cancer patients.
The PROFYLE panel of experts, upon reviewing the findings, considered sertraline to be the most promising treatment option for the patient at that juncture. This expert review process is a critical step in the pathway from research discovery to clinical recommendation, ensuring that novel approaches are vetted by a multidisciplinary team with extensive experience in pediatric oncology.
Promising, Yet Not a Definitive Cure
The initial results of the sertraline treatment were encouraging. Following the commencement of the new therapy, the patient’s tumour growth demonstrably slowed. However, it did not completely halt, indicating that while sertraline offered a significant improvement and a crucial window of opportunity, additional therapeutic strategies would likely be necessary for complete remission.
"While there is certainly more work to be done, this study unequivocally demonstrates that our approach can deliver personalized treatment recommendations swiftly enough to genuinely assist patients with rare and challenging-to-treat cancers," Dr. Lange emphasized. "Our aspiration now is to expand this methodology to benefit other children across the country, enabling us to identify effective treatments with greater speed and precision."
The Broader Implications for Pediatric Cancer Care
The implications of this research extend far beyond the individual patient. This novel integrated approach of proteomics and tumour avatars holds immense potential for transforming the landscape of pediatric cancer treatment.
Accelerated Drug Discovery: The traditional drug development pipeline is notoriously long and expensive. By using tumour avatars, researchers can dramatically shorten the preclinical testing phase, identifying promising drug candidates much faster. This is particularly critical for rare cancers where patient numbers are small, making traditional clinical trials challenging.
Enhanced Treatment Personalization: Genomics has provided invaluable insights into the genetic underpinnings of cancer. However, the proteomic layer offers a more direct view of how the tumour is functioning and what its immediate dependencies are. Combining both genomic and proteomic data allows for a more comprehensive understanding of individual tumour biology, leading to truly personalized treatment plans.
Repurposing Existing Drugs: The study’s success in identifying sertraline, an existing antidepressant, as a potential cancer therapy underscores the significant potential of drug repurposing. This strategy can be considerably faster and more cost-effective than developing entirely new drugs. Identifying novel targets for existing, approved medications can bring new treatment options to patients much sooner.
Addressing Treatment Resistance: Cancer’s ability to develop resistance to therapies is a major hurdle. By analyzing the proteomic changes that occur as tumours become resistant, researchers can better understand the mechanisms of resistance and develop strategies to overcome it, potentially through combination therapies or sequential treatments.
Future Directions and Challenges:
While this study represents a significant leap forward, several avenues for future research and development are evident. Expanding the BRAvE initiative to include a wider range of tumour types and patient populations will be crucial for validating the broader applicability of the chicken egg avatar system. Further research into optimizing the growth conditions and analysis of tumour avatars will enhance their reliability and predictive power.
Moreover, the integration of advanced computational tools and artificial intelligence will be essential for processing the vast amounts of proteomic and genomic data generated, enabling even faster and more accurate treatment recommendations. Continued investment in collaborative research networks like ACCESS and PROFYLE is paramount to sustaining and advancing these innovative approaches.
The successful application of proteomics and tumour avatars in this case offers a beacon of hope for young cancer patients and their families. It signifies a paradigm shift in how we approach cancer treatment, moving towards a future where personalized, precision medicine is not just an aspiration, but a tangible reality, delivered with unprecedented speed and efficacy. The collaborative spirit driving these advancements across Canada positions the nation at the forefront of pediatric cancer research, offering renewed optimism in the fight against this devastating disease.